• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

    5/1/25 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email

    CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets.

    Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. 

    A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Akebia Therapeutics Contact

    Mercedes Carrasco

    [email protected]



    Primary Logo

    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    6/4/2025$8.00Buy
    H.C. Wainwright
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    More analyst ratings

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CFO, CBO & Treasurer Ostrowski Erik sold $151,622 worth of shares (41,314 units at $3.67), decreasing direct ownership by 8% to 503,586 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    7/1/25 5:01:37 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 48% to 109,400 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    6/11/25 5:16:36 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Adams Adrian was granted 35,700 shares, increasing direct ownership by 22% to 200,500 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    6/11/25 5:16:12 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AKBA
    SEC Filings

    View All

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia's common stock on November 28, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.58 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of

    12/1/25 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Announces Establishment of Rare Kidney Disease Pipeline

    Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

    6/4/25 7:33:29 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

    Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

    4/28/25 8:36:09 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Akebia Therapeutics with a new price target

    Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

    4/1/25 9:03:14 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    12/1/25 7:08:46 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    11/17/25 7:54:06 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akebia Therapeutics Inc.

    10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

    11/10/25 7:36:14 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Leadership Updates

    Live Leadership Updates

    View All

    Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

    1/9/24 8:30:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

    11/1/21 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Financials

    Live finance-specific insights

    View All

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Announces Establishment of Rare Kidney Disease Pipeline

    Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ESAs Akebia to host Conference Call at 8:00 a.m. ET on Monday, November 10, 2025 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a b

    11/10/25 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/13/24 4:58:48 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/9/24 4:00:47 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/10/23 1:08:17 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care